Cigna expects revenue gains from launches of Humira biosimilars

<html xmlns=""><head><title>UPDATE 2-Cigna expects revenue gains from launches of Humira biosimilars</title></head><body>

Rewrites, adds management and analyst comments, updates shares

By Leroy Leo

Feb 3 (Reuters) - Cigna Corp CI.N expects its pharmacy benefit management unit to earn more from the second half of 2023 as makers of cheaper versions of AbbVie Inc's ABBV.N arthritis drug Humira will boost aftermarket discounts to gain access to patients.

Amgen Inc AMGN.O launched a biosimilar version of Humira called Amjevita in the United States on Tuesday, and at least seven others are expected to roll out inJuly.

Pharmacy benefit managers (PBMs) act as intermediaries between drugmakers and insurers. They get after-market discounts from drugmakers to add treatments to the lists they recommend to insurers and companies offering coverage for employees.

PBMs typically pass on most of the discounts, called rebates, to their clients and retain some in fees.

Cigna's PBM unit has both Humira and Amgen'sAmjevita on its list of covered drugs.

Chief Executive David Cordani said in a conference call to discuss Cigna's fourth-quarter earnings that he anticipates "value creation from the increased availability of biosimilars building in the second half of 2023 and ramping in 2024 and beyond."

Those gains will help partially offset the anticipated cost this year of setting up its contract to manage Centene Corp's CNC.N annual pharmacy spend of around $40 billion.

Cigna's insurance arm, meanwhile, faces a possible shift towards less profitable government-backed health programs due to chances ofthe U.S. economy's"fragility" pressuring enrollment in corporate plans, Cordani said.

The company forecast amedical care ratio - the ratio of the amount paid out for medical services versus revenue brought in - of 81.5% to 82.5% for 2023. The midpoint is marginally higher than last year's81.7% and a Wall Street estimate of 81.9%.

Its annualprofit forecast of at least $24.60 per share was marginally below expectations of $24.84 per share.

Shares of Cigna were down 1% at $298.44.

Reporting by Leroy Leo in Bengaluru
Editing by Vinay Dwivedi and Devika Syamnath


免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。


本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。